369 related articles for article (PubMed ID: 16906786)
21. Emtricitabine/tenofovir disoproxil fumarate.
Dando TM; Wagstaff AJ
Drugs; 2004; 64(18):2075-82; discussion 2083-4. PubMed ID: 15341498
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
23. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
[TBL] [Abstract][Full Text] [Related]
24. WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Omeje I; Okwundu CI
Cochrane Database Syst Rev; 2012 May; 2012(5):CD007276. PubMed ID: 22592718
[TBL] [Abstract][Full Text] [Related]
25. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.
Llibre JM; Clotet B
AIDS Rev; 2012; 14(3):168-78. PubMed ID: 22833060
[TBL] [Abstract][Full Text] [Related]
26. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
27. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy efavirenz/emtricitabine/tenofovir disoproxil fumarate associated with hepatic failure.
Qayyum S; Dong H; Kovacic D; Sohail S; Waters B; Thornton C; Corbett CE
Curr Drug Saf; 2012 Nov; 7(5):391-3. PubMed ID: 23373554
[TBL] [Abstract][Full Text] [Related]
30. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Lyseng-Williamson KA; Scott LJ
Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
[TBL] [Abstract][Full Text] [Related]
31. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
32. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
[TBL] [Abstract][Full Text] [Related]
33. No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Burger D; van Luin M; Bosch M; van der Ven A; Brouwer AM; Keuter M; Dofferhoff T; Koopmans PP
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):e12-3. PubMed ID: 20647821
[No Abstract] [Full Text] [Related]
34. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Pulido F; Fiorante S
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
[TBL] [Abstract][Full Text] [Related]
35. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
36. The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Killingley B; Pozniak A
Drugs Today (Barc); 2007 Jul; 43(7):427-42. PubMed ID: 17728844
[TBL] [Abstract][Full Text] [Related]
37. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
[TBL] [Abstract][Full Text] [Related]
38. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.
Gazzard BG
Expert Opin Pharmacother; 2006 Apr; 7(6):793-802. PubMed ID: 16556093
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
